Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A new monthly injection for peanut allergy could be a game-changer for kids. PVX108, a peptide-based immunotherapy, more than doubled children's tolerance to peanut protein after 12 months with no serious allergic reactions. The phase II trial results suggest a safer, less burdensome alternative to daily oral immunotherapy.
A novel monthly injection called PVX108 is showing real promise as a safer alternative to existing peanut allergy treatments for children. Unlike traditional immunotherapy that uses whole peanut proteins — which can trigger dangerous reactions — PVX108 uses short peptide fragments that are too small to activate IgE-mediated allergic responses. Instead, they work directly on T cells to promote tolerance, sidestepping the anaphylaxis risk that has long plagued peanut immunotherapy.
In a phase II trial of 71 children aged 4–11, the higher 50 nmol monthly dose increased maximum tolerated peanut doses by 2.4-fold versus 1.2-fold with placebo. Notably, effects persisted or even improved 6 months after treatment ended, hinting at disease-modifying potential. An 87% open-label extension enrollment rate suggests strong patient buy-in.
By the Numbers:
Why it matters: Millions of peanut-allergic patients remain untreated due to the burden and risks of current options. A once-monthly shot with a strong safety profile could dramatically expand access to effective care — especially for young children and families who can't manage daily oral dosing.